A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease
Diseases of the Digestive System - Small Intestines, Large Intestines & Rectum
What is the purpose of this trial?
This is a Phase 3, randomized, double-blind, placebo-controlled study to demonstrate the effect of oral ozanimod as maintenance therapy in subjects with moderately to severely active Crohn's Disease.
- Ages18 years - 75 years
- Trial withCelgene Corporation
- Start Date05/14/2019
- End Date01/31/2021
- Last Updated07/15/2021
- Study HIC#2000024497